| Literature DB >> 32165679 |
S S Rohiwal1, N Dvorakova1, J Klima1, M Vaskovicova1, F Senigl2, M Slouf3, E Pavlova3, P Stepanek3, D Babuka3, H Benes3, Z Ellederova4, K Stieger5.
Abstract
Clustered regularly interspaced short palindromic repeats-associated protein (Entities:
Mesh:
Substances:
Year: 2020 PMID: 32165679 PMCID: PMC7067791 DOI: 10.1038/s41598-020-61465-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Schematic representation of the synthesis of magnetic nanoparticles (MNPs). MNPs are generated by co-precipitation and further complexed with CRISPR/Cas9 plasmids to form a complex, which is transferred into HEK 293-TLE-3 cell line by magnetofection. The nanoparticles are internalized by the cells via endocytosis due to the cationic PEI, which after endocytosis triggers endosomal disruption and causes into the cytoplasm.
Figure 2Hydrodynamic diameter and zeta potential of magnetic nanoparticles (MNPs). (a) Hydrodynamic diameter of MNPs in the presence of water and DMEM at pH 7.0 (mean ± S.D.; n = 3), (b) Zeta potential of T3 and T0-CRISPR/Cas9-PEI-MNPs in the presence of water and DMEM at pH 7.0 (mean ± S.D.; n = 3).
Figure 3Ultrastructure of magnetic nanoparticles (MNPs). TEM micrographs of magnetic-nucleic acid complexes: (a) empty MNPs, (b) empty PEI-MNP, (c) T0-CRISPR/Cas9-PEI-MNPs 0, and (d) T3-CRISPR/Cas9-PEI-MNPs, respectively.
Figure 4FTIR spectroscopy of the generated magnetic nanoparticles (MNPs). (a) MNPs, (b) plasmid DNA, (c) PEI, (d) PEI-MNPs, (e) T0-CRISPR/Cas9-PEI-MNPs and (f) T3-CRISPR/Cas9-PEI-MNPs.
Figure 5Gel electrophoresis retardation assay. (a) PEI-Coated/CRISPR plasmid nanoparticles complexed at an N/P ratio 10 Lane 1: T3-CRISPR/Cas9-PEI-MNPs, Lane 2: T0-CRISPR/Cas9-PEI-MNPs, Lane 3: T3 pure plasmid with restriction enzyme (R.E.), Lane 4: T0 pure plasmid with R.E, Lane 5: ladder 1 KB (b) Characterization of stability in FBS medium of magnetofectins Lane 1: T3-CRISPR/Cas9-PEI-MNPs with R.E., Lane 2: T0-CRISPR/Cas9-PEI-MNPs with R.E., Lane 3: T3 pure plasmid with R.E., Lane 4: T0 pure plasmid with R.E., Lane 5: T3-CRISPR/Cas9-PEI-MNPs without R.E., Lane 6: T0-CRISPR/Cas9-PEI-MNPs without R.E., Lane 7: T3 pure plasmid without R.E., Lane 8: T0 pure plasmid without R.E., Lane 9: ladder 1 KB.
Figure 6Cellular viability assay. Treated and control (untreated) cells at 24 h post treatment with Lipofectamine and PEI-MNPs complex without plasmid. No significant differences in cellular viability compared to untreated cells with p > 0.05 were detected.
Figure 7Quantification of genome editing results in the HEK293-TLR-3 cell line using magnetic nanoparticles (MNPs). (i) FACS representative data of the respective samples and controls with T3 positive control (Lipofectamine), T3-CRISPR/Cas9-PEI-MNPs-M magnetofected, T3-CRISPR/Cas9-PEI-MNPs-X non-magnetofected. (ii) Quantification of the transfection efficacy of NHEJ and HDR values compared with blank, and magnetofected (M) compared with non-magnetofected (X) transfections of the different complexes indicated. Statistical analysis: paired t test, *p < 0.01; **p < 0.001; ***p < 0.0005, ****p < 0.00005 (iii)Design of CRISPR-Cas9 guide RNA Targeting TLR3 Sequence: TargetT3 around the stop codon and I-SceI site (yellow line) have been designed for the specific cleavage within the GFP sequence in the TLR3 system. Depending on the addition of the donor templates, DSBs can be repaired through either NHEJ (BFP) or HDR (GFP). T, target[4].
Figure 8Fluorescent microscopy image of HEK293-TLR-3 cells transfected by T0 and T3 CRISPR/Cas9-PEI-MNPs complex at N/P ratio 10 for 72 h. The percentage of transfection efficiency is determined by mRFP positive cells (a–c), the type of DNA repair mechanism NHEJ and HDR due to the presence of TLR3 sequence is visualized by BFP and GFP respectively, (a) T3 positive control transfected with Lipofectamine, (b) T3-CRISPR/Cas9-PEI-MNPs magentofected and (c) T3-CRISPR/Cas9-PEI-MNPs non-magnetofected.